doxazosin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensive substances, prazosin derivatives	954	74191-85-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: doxazosin doxazosin mesylate doxazosine doxazosin mesilate	A prazosin-related compound that is a selective alpha-1-adrenergic blocker. Molecular weight: 451.48 Formula: C23H25N5O5 CLOGP: 3.58 LIPINSKI: 0 HAC: 10 HDO: 1 TPSA: 112.27 ALOGS: -2.76 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

doxazosin
doxazosin mesylate
doxazosine
doxazosin mesilate

A prazosin-related compound that is a selective alpha-1-adrenergic blocker.

Molecular weight: 451.48
Formula: C23H25N5O5
CLOGP: 3.58
LIPINSKI: 0
HAC: 10
HDO: 1
TPSA: 112.27
ALOGS: -2.76
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
4	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.59 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
Vd (Volume of distribution)	1.30 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	1.60 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.02 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Nov. 2, 1990	FDA	PFIZER

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyperkalaemia	153.16	13.61	125	15986	47964	50541049
Hypotension	123.40	13.61	247	15864	235222	50353791
Hypertensive crisis	114.81	13.61	64	16047	13090	50575923
Syncope	105.23	13.61	146	15965	102856	50486157
Drug interaction	94.58	13.61	201	15910	199420	50389593
Hyponatraemia	84.61	13.61	127	15984	96012	50493001
Acute kidney injury	81.99	13.61	206	15905	227852	50361161
Orthostatic hypotension	55.28	13.61	57	16054	29424	50559589
Bladder prolapse	54.98	13.61	21	16090	1800	50587213
Renal impairment	54.18	13.61	91	16020	75570	50513443
Rectal prolapse	52.19	13.61	20	16091	1729	50587284
Blood pressure increased	46.42	13.61	119	15992	133013	50456000
Hypoglycaemia	45.98	13.61	70	16041	53511	50535502
Bradycardia	45.47	13.61	77	16034	64349	50524664
Gallbladder polyp	43.79	13.61	14	16097	707	50588306
Drug intolerance	42.44	13.61	9	16102	219095	50369918
Dizziness	37.83	13.61	213	15898	346156	50242857
Injection site inflammation	37.59	13.61	19	16092	3186	50585827
Tubulointerstitial nephritis	37.13	13.61	34	16077	15177	50573836
Angioedema	36.32	13.61	52	16059	37624	50551389
Sinus bradycardia	35.21	13.61	31	16080	13152	50575861
Urinary incontinence	34.94	13.61	44	16067	28164	50560849
Sopor	34.69	13.61	37	16074	19842	50569171
Treatment failure	32.83	13.61	3	16108	137634	50451379
Thermal burn	32.82	13.61	20	16091	4821	50584192
Renal artery stenosis	32.31	13.61	14	16097	1658	50587355
Arthropathy	31.58	13.61	6	16105	157900	50431113
Presyncope	30.38	13.61	38	16073	24160	50564853
Maternal exposure during pregnancy	30.05	13.61	7	16104	159771	50429242
Therapeutic product effect decreased	29.83	13.61	4	16107	136046	50452967
Blood pressure inadequately controlled	29.45	13.61	18	16093	4362	50584651
Vitamin D decreased	29.16	13.61	23	16088	8383	50580630
Alopecia	28.26	13.61	22	16089	245025	50343988
Oedema peripheral	28.09	13.61	112	15999	157849	50431164
Blood pressure diastolic decreased	27.13	13.61	30	16081	16751	50572262
Confusional state	27.02	13.61	124	15987	185804	50403209
Drug ineffective	26.59	13.61	153	15958	819180	49769833
Abdominal discomfort	25.22	13.61	22	16089	231619	50357394
Systemic lupus erythematosus	24.82	13.61	7	16104	140615	50448398
Cardiac failure	24.46	13.61	66	16045	75974	50513039
Blood pressure systolic abnormal	24.43	13.61	20	16091	7686	50581327
Blood creatinine increased	24.39	13.61	66	16045	76094	50512919
Renal failure	24.33	13.61	82	16029	106551	50482462
Eye infarction	24.29	13.61	5	16106	40	50588973
Mucosal membrane hyperplasia	23.97	13.61	5	16106	43	50588970
Glossodynia	23.95	13.61	4	16107	115565	50473448
Product use issue	23.65	13.61	9	16102	149466	50439547
Blood pressure diastolic abnormal	22.99	13.61	21	16090	9340	50579673
Loss of consciousness	22.72	13.61	79	16032	104274	50484739
Renin increased	22.70	13.61	6	16105	153	50588860
Clonus	22.69	13.61	15	16096	4160	50584853
Glomerular filtration rate decreased	22.69	13.61	23	16088	11629	50577384
Daydreaming	22.65	13.61	7	16104	316	50588697
Lactic acidosis	22.38	13.61	39	16072	33316	50555697
Off label use	22.33	13.61	77	16034	474349	50114664
Atrial fibrillation	22.13	13.61	77	16034	101668	50487345
Feeling cold	21.89	13.61	29	16082	19502	50569511
Blood urea increased	20.48	13.61	31	16080	23554	50565459
Anaemia	20.47	13.61	144	15967	252312	50336701
Post cardiac arrest syndrome	20.44	13.61	4	16107	24	50588989
Pain	20.43	13.61	105	16006	578798	50010215
Cardiac failure congestive	20.24	13.61	66	16045	84316	50504697
Sinusitis	20.05	13.61	15	16096	170543	50418470
Hyperreflexia	19.93	13.61	15	16096	5103	50583910
Blood potassium increased	19.39	13.61	25	16086	16373	50572640
Metabolic acidosis	19.36	13.61	40	16071	38785	50550228
Hypertensive encephalopathy	18.59	13.61	7	16104	577	50588436
Blood pressure decreased	18.45	13.61	49	16062	55860	50533153
Oral discharge	17.89	13.61	5	16106	158	50588855
Hepatic enzyme increased	17.59	13.61	11	16100	137369	50451644
Malignant hypertension	17.57	13.61	8	16103	1066	50587947
Angiosclerosis	17.00	13.61	3	16108	9	50589004
Circulatory collapse	16.96	13.61	26	16085	19974	50569039
Familial periodic paralysis	16.96	13.61	4	16107	63	50588950
Dyspnoea	16.90	13.61	256	15855	547352	50041661
Duodenal ulcer	16.25	13.61	15	16096	6760	50582253
Swollen tongue	16.08	13.61	31	16080	28599	50560414
Product dose omission issue	16.05	13.61	21	16090	183817	50405196
Vision blurred	15.79	13.61	58	16053	78589	50510424
Bradyphrenia	15.50	13.61	14	16097	6138	50582875
Simple partial seizures	15.41	13.61	6	16105	541	50588472
Therapeutic product effect incomplete	15.34	13.61	5	16106	91510	50497503
Hypokalaemia	15.31	13.61	62	16049	87930	50501083
Fasting	15.05	13.61	3	16108	20	50588993
Discomfort	14.83	13.61	8	16103	108372	50480641
Injection site erythema	14.65	13.61	3	16108	74933	50514080
Gingival bleeding	14.52	13.61	18	16093	11335	50577678
Muscle twitching	14.43	13.61	21	16090	15410	50573603
Chronic kidney disease	14.30	13.61	36	16075	39735	50549278
Heart rate decreased	14.14	13.61	34	16077	36463	50552550
Nephrogenic anaemia	14.07	13.61	8	16103	1697	50587316
Rheumatoid arthritis	14.02	13.61	27	16084	202523	50386490
Pemphigoid	14.02	13.61	13	16098	5894	50583119
Periorbital oedema	13.81	13.61	12	16099	5000	50584013

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Syncope	132.64	11.26	281	31900	81090	29461256
Orthostatic hypotension	90.10	11.26	117	32064	22512	29519834
Off label use	75.13	11.26	133	32048	300667	29241679
Hypertensive crisis	73.49	11.26	64	32117	7784	29534562
Blood pressure inadequately controlled	61.27	11.26	36	32145	2350	29539996
Middle insomnia	58.45	11.26	49	32132	5659	29536687
Mycotic allergy	56.77	11.26	18	32163	246	29542100
Febrile neutropenia	54.52	11.26	27	32154	112213	29430133
Carotid arteriosclerosis	54.34	11.26	28	32153	1410	29540936
Mite allergy	53.54	11.26	18	32163	299	29542047
Asthma	52.86	11.26	115	32066	33734	29508612
Full blood count abnormal	51.18	11.26	72	32109	14941	29527405
Hypotension	51.12	11.26	374	31807	193980	29348366
Conjunctivitis allergic	50.92	11.26	21	32160	629	29541717
Spirometry abnormal	50.48	11.26	18	32163	359	29541987
Dust allergy	49.47	11.26	19	32162	470	29541876
Presyncope	48.79	11.26	73	32108	16016	29526330
Drug interaction	48.05	11.26	373	31808	197012	29345334
Drug abuse	45.65	11.26	15	32166	79868	29462478
Left ventricular hypertrophy	44.20	11.26	45	32136	6658	29535688
Hyperkalaemia	44.09	11.26	157	32024	61235	29481111
Renal cyst haemorrhage	41.92	11.26	16	32165	389	29541957
Bradycardia	40.61	11.26	160	32021	65469	29476877
Productive cough	39.78	11.26	98	32083	31161	29511185
Neutropenia	39.76	11.26	51	32130	131660	29410686
Tricuspid valve incompetence	37.52	11.26	46	32135	8348	29533998
Oedema peripheral	36.75	11.26	215	31966	103342	29439004
Dizziness	35.88	11.26	339	31842	189345	29353001
Blood creatinine increased	35.76	11.26	185	31996	84917	29457429
Gastrointestinal tract mucosal pigmentation	35.62	11.26	14	32167	369	29541977
Ventricular hyperkinesia	35.49	11.26	12	32169	203	29542143
Loss of consciousness	34.67	11.26	166	32015	73890	29468456
Hypertensive heart disease	34.66	11.26	24	32157	2083	29540263
Right atrial enlargement	34.24	11.26	12	32169	227	29542119
Atrial fibrillation	32.85	11.26	212	31969	105434	29436912
Rectal prolapse	32.77	11.26	12	32169	259	29542087
Mitral valve thickening	32.48	11.26	13	32168	360	29541986
Aortic valve incompetence	31.87	11.26	33	32148	4980	29537366
Renal artery stenosis	31.47	11.26	22	32159	1939	29540407
Hypochromasia	31.24	11.26	12	32169	297	29542049
SARS-CoV-2 antibody test positive	30.73	11.26	11	32170	222	29542124
Mean platelet volume increased	30.37	11.26	13	32168	428	29541918
Drug ineffective	30.12	11.26	252	31929	362918	29179428
Nephrectomy	29.91	11.26	15	32166	713	29541633
Death	29.91	11.26	234	31947	341850	29200496
Mycobacterium test positive	28.56	11.26	12	32169	377	29541969
Left ventricular enlargement	28.46	11.26	14	32167	638	29541708
Subacute hepatic failure	28.06	11.26	8	32173	74	29542272
Floppy iris syndrome	27.77	11.26	11	32170	296	29542050
Vena cava injury	27.65	11.26	10	32171	208	29542138
Wheezing	27.35	11.26	89	32092	33151	29509195
Intraductal papillary mucinous neoplasm	26.69	11.26	11	32170	329	29542017
Renal impairment	26.38	11.26	165	32016	81168	29461178
Hyperparathyroidism	26.20	11.26	16	32165	1121	29541225
Haemodialysis	25.77	11.26	42	32139	9912	29532434
Myopathy	25.33	11.26	43	32138	10490	29531856
Normochromic normocytic anaemia	24.93	11.26	25	32156	3633	29538713
Primary hyperaldosteronism	24.92	11.26	7	32174	61	29542285
Electrocardiogram T wave inversion	24.38	11.26	19	32162	1978	29540368
Lung diffusion test decreased	23.84	11.26	12	32169	575	29541771
Blood urea increased	23.79	11.26	76	32105	28036	29514310
Left atrial enlargement	23.76	11.26	13	32168	740	29541606
Septic shock	23.61	11.26	20	32161	62540	29479806
Angioedema	23.22	11.26	82	32099	31833	29510513
Vertigo	23.16	11.26	64	32117	21797	29520549
Acute kidney injury	23.13	11.26	411	31770	264856	29277490
Mitral valve incompetence	22.87	11.26	47	32134	13246	29529100
Aortic dilatation	22.87	11.26	14	32167	985	29541361
Tooth avulsion	22.46	11.26	5	32176	14	29542332
Completed suicide	22.33	11.26	40	32141	90206	29452140
Arteriosclerosis	22.24	11.26	40	32141	10216	29532130
Bundle branch block left	22.11	11.26	28	32153	5249	29537097
Orthopnoea	22.03	11.26	26	32155	4534	29537812
Mucosal inflammation	21.79	11.26	4	32177	31591	29510755
Nocturia	21.26	11.26	35	32146	8327	29534019
Product use issue	21.25	11.26	15	32166	51429	29490917
Treatment failure	20.98	11.26	7	32174	36932	29505414
Cardiac autonomic neuropathy	20.45	11.26	6	32175	62	29542284
Obstructive airways disorder	20.20	11.26	40	32141	10976	29531370
Thrombocytopenia	20.15	11.26	77	32104	134746	29407600
Hyperparathyroidism secondary	19.75	11.26	14	32167	1261	29541085
Metabolic acidosis	19.51	11.26	87	32094	37575	29504771
Urine flow decreased	19.16	11.26	13	32168	1091	29541255
Hypertension	18.90	11.26	202	31979	116412	29425934
Atrioventricular block first degree	18.86	11.26	26	32155	5293	29537053
Atrioventricular block	18.81	11.26	30	32151	6952	29535394
Shock hypoglycaemic	18.05	11.26	6	32175	96	29542250
Scrotal oedema	18.02	11.26	14	32167	1450	29540896
Sprue-like enteropathy	17.88	11.26	9	32172	431	29541915
High density lipoprotein decreased	17.85	11.26	19	32162	2960	29539386
Arteriosclerosis coronary artery	17.66	11.26	37	32144	10568	29531778
Chronic kidney disease	17.29	11.26	82	32099	36334	29506012
Angina pectoris	17.29	11.26	68	32113	27782	29514564
Blood pressure ambulatory increased	17.19	11.26	5	32176	50	29542296
Inappropriate schedule of product administration	17.05	11.26	14	32167	44458	29497888
Human polyomavirus infection	16.63	11.26	10	32171	681	29541665
Delayed graft function	16.61	11.26	15	32166	1912	29540434
Haematuria	16.51	11.26	93	32088	44046	29498300
Chronic obstructive pulmonary disease	16.47	11.26	88	32093	40867	29501479
Psychotic symptom	16.28	11.26	13	32168	1401	29540945
Benign prostatic hyperplasia	16.27	11.26	38	32143	11672	29530674
Large intestine polyp	16.22	11.26	27	32154	6482	29535864
Palpitations	15.90	11.26	74	32107	32530	29509816
Abdominal wall haemorrhage	15.85	11.26	7	32174	249	29542097
Drug monitoring procedure not performed	15.74	11.26	7	32174	253	29542093
Xanthopsia	15.71	11.26	6	32175	146	29542200
Hypoglycaemia	15.61	11.26	98	32083	48248	29494098
Myocardial infarction	15.57	11.26	186	31995	110110	29432236
Genital swelling	15.45	11.26	6	32175	153	29542193
Crystalluria	15.45	11.26	8	32173	407	29541939
Dilatation ventricular	15.40	11.26	16	32165	2424	29539922
Diastolic dysfunction	15.38	11.26	23	32158	5041	29537305
Spinal osteoarthritis	15.35	11.26	26	32155	6330	29536016
Sepsis	15.18	11.26	92	32089	142590	29399756
Product dose omission issue	15.07	11.26	54	32127	96329	29446017
Pyrexia	14.86	11.26	222	31959	287400	29254946
Renal cyst	14.85	11.26	29	32152	7878	29534468
Dermatosis	14.81	11.26	7	32174	292	29542054
Product use in unapproved indication	14.72	11.26	47	32134	86828	29455518
Obstruction	14.69	11.26	14	32167	1912	29540434
Spermatozoa progressive motility abnormal	14.66	11.26	4	32177	31	29542315
Toxicity to various agents	14.55	11.26	120	32061	173541	29368805
Supine hypertension	14.52	11.26	7	32174	305	29542041
Electrocardiogram ST segment elevation	14.51	11.26	21	32160	4471	29537875
Microalbuminuria	14.37	11.26	9	32172	659	29541687
Infusion related reaction	14.27	11.26	16	32165	43870	29498476
Aplasia pure red cell	13.98	11.26	23	32158	5468	29536878
Asthenia	13.88	11.26	319	31862	214931	29327415
Rhabdomyolysis	13.68	11.26	113	32068	60695	29481651
Hospitalisation	13.65	11.26	18	32163	45970	29496376
Ischaemic cardiomyopathy	13.53	11.26	23	32158	5615	29536731
Duplicate therapy error	13.48	11.26	5	32176	112	29542234
Blood phosphorus increased	13.42	11.26	16	32165	2821	29539525
Melaena	13.23	11.26	68	32113	31108	29511238
Malignant neoplasm progression	13.20	11.26	39	32142	73820	29468526
Leukopenia	13.17	11.26	25	32156	55178	29487168
Blood uric acid increased	13.15	11.26	23	32158	5745	29536601
Multiple organ dysfunction syndrome	13.04	11.26	31	32150	63085	29479261
Vitamin D decreased	13.02	11.26	16	32165	2909	29539437
Renal failure	13.00	11.26	191	31990	118408	29423938
Blood pressure increased	12.96	11.26	130	32051	73673	29468673
Glomerular filtration rate decreased	12.95	11.26	34	32147	11232	29531114
Respiratory failure	12.92	11.26	58	32123	97073	29445273
Cardio-respiratory arrest	12.90	11.26	22	32159	50579	29491767
Sinus node dysfunction	12.86	11.26	18	32163	3716	29538630
Myalgia	12.82	11.26	130	32051	73889	29468457
Spermatozoa progressive motility decreased	12.75	11.26	5	32176	131	29542215
Disease progression	12.74	11.26	46	32135	81870	29460476
Sinus rhythm	12.50	11.26	6	32175	259	29542087
Toxic neuropathy	12.48	11.26	7	32174	418	29541928
Blood pressure systolic decreased	12.46	11.26	18	32163	3826	29538520
Blood chloride increased	12.36	11.26	15	32166	2694	29539652
Aortic arteriosclerosis	12.34	11.26	18	32163	3858	29538488
Myopathy toxic	12.30	11.26	7	32174	430	29541916
Post transplant distal limb syndrome	12.03	11.26	6	32175	282	29542064
Jaundice hepatocellular	11.98	11.26	4	32177	65	29542281
Chronic fatigue syndrome	11.89	11.26	6	32175	289	29542057
Pneumonia	11.84	11.26	262	31919	319910	29222436
Blood potassium increased	11.84	11.26	39	32142	14612	29527734
Haemoglobinaemia	11.79	11.26	5	32176	161	29542185
Mean cell volume increased	11.71	11.26	14	32167	2475	29539871
Cerebral haemorrhage	11.61	11.26	66	32115	31360	29510986
Vascular compression	11.59	11.26	5	32176	168	29542178
Agitation	11.58	11.26	24	32157	51280	29491066
Diverticulum intestinal	11.54	11.26	16	32165	3274	29539072
Tongue haemorrhage	11.48	11.26	7	32174	489	29541857
Mouth breathing	11.45	11.26	4	32177	75	29542271
Breath sounds	11.38	11.26	3	32178	20	29542326
Eosinophilia	11.33	11.26	51	32130	22110	29520236

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Syncope	229.43	11.03	388	41923	157247	64299174
Hypertensive crisis	185.07	11.03	127	42184	18121	64438300
Hyperkalaemia	180.05	11.03	273	42038	100856	64355565
Drug interaction	144.61	11.03	543	41768	361540	64094881
Hypotension	142.06	11.03	559	41752	380415	64076006
Orthostatic hypotension	140.21	11.03	163	42148	46575	64409846
Acute kidney injury	99.63	11.03	567	41744	448673	64007748
Bradycardia	86.14	11.03	219	42092	118000	64338421
Off label use	85.37	11.03	180	42131	632626	63823795
Renal impairment	80.22	11.03	232	42079	134785	64321636
Rectal prolapse	76.07	11.03	32	42279	1694	64454727
Presyncope	69.98	11.03	100	42211	34989	64421432
Blood pressure inadequately controlled	68.02	11.03	43	42268	5341	64451080
Carotid arteriosclerosis	64.10	11.03	30	42281	2049	64454372
Renal artery stenosis	59.53	11.03	32	42279	2937	64453484
Atrial fibrillation	58.71	11.03	245	42066	170844	64285577
Blood creatinine increased	58.50	11.03	209	42102	135573	64320848
Middle insomnia	58.40	11.03	56	42255	12821	64443600
Dizziness	57.10	11.03	479	41832	429684	64026737
Drug ineffective	55.66	11.03	324	41987	839923	63616498
Angioedema	54.11	11.03	123	42188	61698	64394723
Alopecia	53.26	11.03	21	42290	165669	64290752
Hyponatraemia	52.91	11.03	215	42096	148124	64308297
Febrile neutropenia	52.28	11.03	29	42282	187628	64268793
Loss of consciousness	51.31	11.03	213	42098	148152	64308269
Hypoglycaemia	51.00	11.03	152	42159	89740	64366681
Oedema peripheral	50.81	11.03	272	42039	210045	64246376
Left ventricular hypertrophy	50.19	11.03	45	42266	9461	64446960
Conjunctivitis allergic	48.44	11.03	20	42291	1010	64455411
Treatment failure	48.41	11.03	9	42302	116807	64339614
Spirometry abnormal	48.09	11.03	17	42294	559	64455862
Renal cyst haemorrhage	47.77	11.03	16	42295	446	64455975
Contraindicated product administered	47.59	11.03	7	42304	107822	64348599
Product use issue	47.51	11.03	20	42291	151695	64304726
Full blood count abnormal	46.86	11.03	76	42235	29681	64426740
Blood urea increased	46.86	11.03	95	42216	44058	64412363
Bladder prolapse	46.46	11.03	20	42291	1121	64455300
Drug intolerance	45.61	11.03	34	42277	187958	64268463
Maternal exposure during pregnancy	45.28	11.03	5	42306	95879	64360542
Pain	44.75	11.03	199	42112	553312	63903109
Mite allergy	44.32	11.03	17	42294	706	64455715
Metabolic acidosis	43.14	11.03	123	42188	70835	64385586
Renal failure	42.53	11.03	233	42078	181455	64274966
Dust allergy	41.38	11.03	18	42293	1035	64455386
Mycotic allergy	39.02	11.03	17	42294	981	64455440
Ventricular hyperkinesia	38.64	11.03	12	42299	261	64456160
Sinusitis	38.59	11.03	24	42287	145904	64310517
Mitral valve thickening	37.97	11.03	13	42298	388	64456033
Vitamin D decreased	37.86	11.03	35	42276	7652	64448769
Neutropenia	37.62	11.03	62	42249	239562	64216859
Glomerular filtration rate decreased	36.43	11.03	54	42257	19518	64436903
Right atrial enlargement	36.22	11.03	12	42299	323	64456098
Tricuspid valve incompetence	36.18	11.03	50	42261	16953	64439468
Aortic valve incompetence	35.58	11.03	35	42276	8266	64448155
SARS-CoV-2 antibody test positive	35.47	11.03	11	42300	238	64456183
Hypertensive heart disease	35.11	11.03	25	42286	3779	64452642
Therapeutic product effect decreased	34.85	11.03	16	42295	115335	64341086
Left ventricular enlargement	34.62	11.03	14	42297	670	64455751
Productive cough	34.38	11.03	116	42195	73087	64383334
Arteriosclerosis	34.25	11.03	47	42264	15830	64440591
Mycobacterium test positive	33.73	11.03	12	42299	402	64456019
Mitral valve incompetence	33.32	11.03	60	42251	25478	64430943
Cardiac failure	33.17	11.03	173	42138	132200	64324221
Benign prostatic hyperplasia	32.68	11.03	35	42276	9130	64447291
Hepatic enzyme increased	32.16	11.03	23	42288	129920	64326501
Systemic lupus erythematosus	32.11	11.03	6	42305	77606	64378815
Vena cava injury	32.09	11.03	10	42301	220	64456201
Rheumatoid arthritis	31.28	11.03	37	42274	164257	64292164
Gastrointestinal tract mucosal pigmentation	30.52	11.03	14	42297	913	64455508
Nephrectomy	30.41	11.03	16	42295	1406	64455015
Sopor	29.33	11.03	62	42249	29599	64426822
Chronic kidney disease	29.18	11.03	94	42217	57825	64398596
Arthropathy	29.17	11.03	22	42289	120945	64335476
Completed suicide	29.16	11.03	65	42246	224349	64232072
Product dose omission issue	29.08	11.03	52	42259	194695	64261726
Hypochromasia	28.30	11.03	12	42299	648	64455773
Primary hyperaldosteronism	28.00	11.03	8	42303	129	64456292
Melaena	27.98	11.03	88	42223	53460	64402961
Blood pressure increased	27.70	11.03	201	42110	172351	64284070
Gallbladder polyp	27.62	11.03	13	42298	899	64455522
Scrotal oedema	27.01	11.03	14	42297	1193	64455228
Mean platelet volume increased	26.76	11.03	13	42298	965	64455456
Pemphigus	26.64	11.03	4	42307	60697	64395724
Rhabdomyolysis	26.61	11.03	125	42186	91601	64364820
Blood potassium increased	26.50	11.03	55	42256	25925	64430496
Sinus bradycardia	26.39	11.03	51	42260	22842	64433579
Circulatory collapse	26.12	11.03	64	42247	33668	64422753
Intraductal papillary mucinous neoplasm	26.08	11.03	11	42300	586	64455835
Cardiac failure congestive	25.69	11.03	160	42151	130420	64326001
Nocturia	25.53	11.03	34	42277	11131	64445290
Abdominal discomfort	25.19	11.03	51	42260	182271	64274150
Asthenia	25.06	11.03	407	41904	427637	64028784
Injection site inflammation	24.85	11.03	19	42292	3202	64453219
Infusion related reaction	24.47	11.03	44	42267	164423	64291998
Subacute hepatic failure	24.45	11.03	8	42303	207	64456214
Angina pectoris	24.39	11.03	75	42236	45006	64411415
Floppy iris syndrome	24.38	11.03	9	42302	336	64456085
Ischaemic cardiomyopathy	24.18	11.03	26	42285	6812	64449609
Nasopharyngitis	23.70	11.03	59	42252	196014	64260407
Blood uric acid increased	23.68	11.03	28	42283	8135	64448286
Haemodialysis	23.41	11.03	41	42270	17036	64439385
Urine flow decreased	23.34	11.03	12	42299	1005	64455416
Left atrial enlargement	23.18	11.03	12	42299	1020	64455401
Wheezing	22.78	11.03	109	42202	80470	64375951
Orthopnoea	22.73	11.03	29	42282	9105	64447316
Injection site erythema	22.69	11.03	9	42302	70791	64385630
Arteriosclerosis coronary artery	22.22	11.03	38	42273	15491	64440930
Haematuria	21.81	11.03	88	42223	60383	64396038
Swollen tongue	21.63	11.03	61	42250	34893	64421528
Lung diffusion test decreased	21.52	11.03	12	42299	1184	64455237
Hypertension	21.39	11.03	262	42049	258999	64197422
Obstructive airways disorder	21.25	11.03	47	42264	23138	64433283
Normochromic normocytic anaemia	21.17	11.03	24	42287	6666	64449755
End stage renal disease	21.09	11.03	30	42281	10445	64445976
Coronary artery disease	21.05	11.03	87	42224	60346	64396075
Dermatosis	21.03	11.03	9	42302	497	64455924
Death	20.96	11.03	209	42102	482496	63973925
Sinus node dysfunction	20.77	11.03	24	42287	6804	64449617
Chronic obstructive pulmonary disease	20.73	11.03	97	42214	70951	64385470
Atrioventricular block	20.73	11.03	32	42279	11983	64444438
Angiosclerosis	20.61	11.03	4	42307	9	64456412
Bundle branch block left	20.59	11.03	29	42282	10005	64446416
Myocardial infarction	20.52	11.03	182	42129	165639	64290782
Discomfort	20.42	11.03	14	42297	80864	64375557
Mucosal membrane hyperplasia	20.27	11.03	5	42306	44	64456377
Exposure during pregnancy	20.21	11.03	13	42298	77662	64378759
Hyperparathyroidism	20.21	11.03	16	42295	2836	64453585
Tubulointerstitial nephritis	20.17	11.03	55	42256	30854	64425567
Product use in unapproved indication	19.93	11.03	55	42256	176563	64279858
Myopathy	19.90	11.03	39	42272	17641	64438780
Infection	19.81	11.03	59	42252	184821	64271600
Cerebral haemorrhage	19.76	11.03	76	42235	51014	64405407
Drug monitoring procedure not performed	19.74	11.03	10	42301	812	64455609
Aortic dilatation	19.74	11.03	12	42299	1391	64455030
Blood pressure ambulatory increased	19.60	11.03	5	42306	51	64456370
Cardiac autonomic neuropathy	19.60	11.03	5	42306	51	64456370
High density lipoprotein decreased	19.50	11.03	18	42293	3928	64452493
Glossodynia	19.50	11.03	9	42302	64687	64391734
Dyspnoea	19.37	11.03	612	41699	718062	63738359
Abdominal wall haemorrhage	19.13	11.03	8	42303	417	64456004
Hypokalaemia	18.98	11.03	141	42170	121762	64334659
Large intestine polyp	18.89	11.03	29	42282	10808	64445613
Kidney transplant rejection	18.80	11.03	27	42284	9484	64446937
Thermal burn	18.37	11.03	21	42290	5885	64450536
Renal cyst	18.30	11.03	31	42280	12539	64443882
Nausea	17.74	11.03	387	41924	785413	63671008
Urinary incontinence	17.60	11.03	58	42253	36093	64420328
Post cardiac arrest syndrome	17.55	11.03	4	42307	24	64456397
Psychotic symptom	17.35	11.03	13	42298	2125	64454296
Delayed graft function	17.28	11.03	15	42296	3021	64453400
Rectal haemorrhage	17.02	11.03	83	42228	61734	64394687
Rash	16.92	11.03	206	42105	458343	63998078
Flushing	16.88	11.03	16	42295	78632	64377789
Acute myocardial infarction	16.68	11.03	90	42221	69628	64386793
Spermatozoa progressive motility abnormal	16.66	11.03	4	42307	31	64456390
Stomatitis	16.59	11.03	29	42282	109576	64346845
Blood chloride increased	16.52	11.03	18	42293	4785	64451636
Cerebrovascular accident	16.50	11.03	150	42161	137433	64318988
Electrocardiogram ST segment elevation	16.43	11.03	22	42289	7237	64449184
Renin increased	16.40	11.03	6	42305	218	64456203
Hyperparathyroidism secondary	16.36	11.03	13	42298	2317	64454104
Muscular dystrophy	16.35	11.03	5	42306	103	64456318
Electrocardiogram T wave inversion	16.24	11.03	18	42293	4876	64451545
Fasting	16.23	11.03	4	42307	35	64456386
Nephrogenic anaemia	16.11	11.03	15	42296	3310	64453111
Haemoglobin decreased	16.02	11.03	197	42114	194866	64261555
Drug abuse	15.86	11.03	40	42271	132334	64324087
Joint swelling	15.83	11.03	80	42231	215302	64241119
Shock hypoglycaemic	15.76	11.03	6	42305	244	64456177
Priapism	15.65	11.03	16	42295	3954	64452467
Simple partial seizures	15.64	11.03	8	42303	663	64455758
Erectile dysfunction	15.63	11.03	29	42282	12598	64443823
Injection site pruritus	15.48	11.03	3	42308	37823	64418598
Vertigo	15.38	11.03	78	42233	58933	64397488
Human polyomavirus infection	15.07	11.03	9	42302	1010	64455411
Eosinophilia	15.02	11.03	57	42254	38019	64418402
Atrioventricular block first degree	15.01	11.03	26	42285	10708	64445713
Sprue-like enteropathy	14.99	11.03	9	42302	1020	64455401
Prostatic haemorrhage	14.77	11.03	5	42306	144	64456277
Asthma	14.74	11.03	110	42201	95115	64361306
Anuria	14.70	11.03	36	42275	18928	64437493
Clonus	14.68	11.03	19	42292	6048	64450373
Obstruction	14.49	11.03	14	42297	3234	64453187
Genital swelling	14.44	11.03	6	42305	308	64456113
Blood phosphorus increased	14.40	11.03	17	42294	4929	64451492
Gastrointestinal disorder	14.26	11.03	23	42288	89686	64366735
Spermatozoa progressive motility decreased	14.21	11.03	4	42307	61	64456360
Arthralgia	14.01	11.03	205	42106	442055	64014366
Crystalluria	13.97	11.03	8	42303	830	64455591
Electrocardiogram T wave peaked	13.93	11.03	8	42303	835	64455586
Herpes zoster	13.85	11.03	19	42292	79168	64377253
Aortic valve sclerosis	13.71	11.03	10	42301	1569	64454852
Tooth avulsion	13.64	11.03	4	42307	71	64456350
Supine hypertension	13.63	11.03	6	42305	355	64456066
Ventricular hypertrophy	13.62	11.03	19	42292	6497	64449924
Nephrogenic systemic fibrosis	13.56	11.03	18	42293	5874	64450547
Ill-defined disorder	13.47	11.03	6	42305	44046	64412375
Therapeutic product effect incomplete	13.40	11.03	30	42281	103452	64352969
Feeling cold	13.38	11.03	40	42271	23638	64432783
Septic shock	13.31	11.03	31	42280	105406	64351015
Injection site reaction	13.29	11.03	7	42304	46657	64409764
Chills	13.17	11.03	46	42265	137218	64319203
Hyperlipidaemia	13.16	11.03	39	42272	22937	64433484
Bronchiolitis	13.15	11.03	14	42297	3627	64452794
Duplicate therapy error	13.14	11.03	5	42306	203	64456218
Toxicity to various agents	13.14	11.03	164	42147	363349	64093072
Vascular anastomotic haemorrhage	13.01	11.03	4	42307	84	64456337
Myalgia	12.93	11.03	160	42151	158457	64297964
Perineal cyst	12.92	11.03	4	42307	86	64456335
Diabetic nephropathy	12.91	11.03	12	42299	2642	64453779
Fatigue	12.79	11.03	384	41927	748346	63708075
Oliguria	12.74	11.03	29	42282	14547	64441874
Angina unstable	12.67	11.03	30	42281	15437	64440984
Disease progression	12.60	11.03	49	42262	141631	64314790
Aplasia pure red cell	12.55	11.03	19	42292	6995	64449426
Shock	12.50	11.03	54	42257	38186	64418235
Condition aggravated	12.37	11.03	171	42140	372255	64084166
Blood glucose increased	12.30	11.03	108	42203	97965	64358456
Ventricular extrasystoles	12.26	11.03	32	42279	17497	64438924
Bundle branch block	12.23	11.03	9	42302	1431	64454990
Anaemia	12.21	11.03	330	41981	378350	64078071
Oral discharge	12.06	11.03	5	42306	255	64456166
Haemoglobinaemia	12.04	11.03	5	42306	256	64456165
Multiple sclerosis relapse	11.97	11.03	6	42305	41129	64415292
Vascular compression	11.77	11.03	5	42306	271	64456150
Duodenal ulcer perforation	11.77	11.03	4	42307	34621	64421800
Periorbital oedema	11.76	11.03	19	42292	7395	64449026
Tachyarrhythmia	11.75	11.03	17	42294	6009	64450412
Jaundice hepatocellular	11.70	11.03	4	42307	119	64456302
Toxic neuropathy	11.69	11.03	7	42304	789	64455632
Coronary artery stenosis	11.69	11.03	24	42287	11224	64445197
Ejaculation disorder	11.68	11.03	6	42305	502	64455919
Aortic arteriosclerosis	11.64	11.03	19	42292	7457	64448964
Optic neuropathy	11.63	11.03	12	42299	2999	64453422
Daydreaming	11.58	11.03	7	42304	803	64455618
Blood lactic acid abnormal	11.56	11.03	3	42308	33	64456388
Neuropathy peripheral	11.54	11.03	39	42272	117486	64338935
Cardiomegaly	11.53	11.03	38	42273	23646	64432775
Anti-erythropoietin antibody negative	11.49	11.03	5	42306	288	64456133
Post transplant distal limb syndrome	11.44	11.03	6	42305	524	64455897
Proteinuria	11.35	11.03	42	42269	27681	64428740
Mouth breathing	11.33	11.03	4	42307	131	64456290
Lactic acidosis	11.30	11.03	74	42237	61336	64395085
Phaeochromocytoma crisis	11.26	11.03	5	42306	302	64456119
Hepatocellular injury	11.19	11.03	8	42303	45227	64411194
Tongue haemorrhage	11.17	11.03	7	42304	856	64455565
Xanthopsia	11.17	11.03	5	42306	308	64456113
Sepsis	11.14	11.03	97	42214	230244	64226177
Haemorrhage subcutaneous	11.09	11.03	14	42297	4347	64452074
Folliculitis	11.08	11.03	3	42308	30074	64426347
Gravitational oedema	11.04	11.03	9	42302	1663	64454758

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02CA04	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING Alpha-adrenoreceptor antagonists
FDA MoA	N0000000099	Adrenergic alpha-Antagonists
FDA EPC	N0000175553	alpha-Adrenergic Blocker
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:35674	antihypertensive drugs
CHEBI has role	CHEBI:37890	alpha-adrenergic receptor blockaders
CHEBI has role	CHEBI:59844	antihyperplasia drugs
MeSH PA	D018663	Adrenergic Agents
MeSH PA	D058668	Adrenergic alpha-1 Receptor Antagonists
MeSH PA	D000317	Adrenergic alpha-Antagonists
MeSH PA	D018674	Adrenergic Antagonists
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018377	Neurotransmitter Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Benign prostatic hyperplasia	indication	266569009
Priapism	contraindication	6273006	DOID:9286
Stenosis of intestine	contraindication	23065003
Orthostatic hypotension	contraindication	28651003
Low blood pressure	contraindication	45007003
Hepatic failure	contraindication	59927004
Chronic idiopathic constipation	contraindication	82934008
Cataract surgery	contraindication	110473004
Disease of liver	contraindication	235856003	DOID:409
Pyloric obstruction	contraindication	244815007
Syncope	contraindication	271594007
Intraoperative floppy iris syndrome	contraindication	418801006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.22	Basic
pKa2	0.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Alpha-1D adrenergic receptor	GPCR	P25100	ADA1D_HUMAN	ANTAGONIST	Ki	8.85	WOMBAT-PK	CHEMBL
Alpha-1B adrenergic receptor	GPCR	P35368	ADA1B_HUMAN	ANTAGONIST	Ki	9.10	WOMBAT-PK	CHEMBL
Alpha-1A adrenergic receptor	GPCR	P35348	ADA1A_HUMAN	ANTAGONIST	Ki	8.80	WOMBAT-PK	CHEMBL
Potassium voltage-gated channel subfamily H member 2	Ion channel	Q12809	KCNH2_HUMAN		IC50	6.23	WOMBAT-PK
Multidrug resistance protein 1	Transporter	P08183	MDR1_HUMAN		Ki	5	WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN		Ki	5.85	DRUG MATRIX
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN		Ki	6.63	DRUG MATRIX
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN		Ki	6.55	DRUG MATRIX
Alpha-2C adrenergic receptor	GPCR	P18825	ADA2C_HUMAN		Ki	6.55	CHEMBL
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		Ki	6.83	DRUG MATRIX
Interstitial collagenase	Enzyme	P03956	MMP1_HUMAN		IC50	5.24	DRUG MATRIX
HLA class I histocompatibility antigen, A-3 alpha chain	Unclassified	P04439	1A03_HUMAN		Kd	4.80	CHEMBL
Beta-2 adrenergic receptor	GPCR	P07550	ADRB2_HUMAN		Ki	5.72	DRUG MATRIX
Alpha-2A adrenergic receptor	GPCR	P08913	ADA2A_HUMAN		Ki	6.14	CHEMBL
Alpha-1B adrenergic receptor	GPCR		ADA1B_RAT		Ki	9.38	DRUG MATRIX
Alpha-1A adrenergic receptor	GPCR		ADA1A_RAT		IC50	8.81	CHEMBL
5-hydroxytryptamine receptor 4	GPCR		5HT4R_CAVPO		Ki	6.90	DRUG MATRIX

External reference:

ID	Source
4019735	VUID
N0000147827	NUI
D00608	KEGG_DRUG
77883-43-3	SECONDARY_CAS_RN
4019565	VANDF
4019735	VANDF
C0114873	UMLSCUI
CHEBI:4708	CHEBI
CHEMBL707	ChEMBL_ID
CHEMBL1200561	ChEMBL_ID
D017292	MESH_DESCRIPTOR_UI
DB00590	DRUGBANK_ID
7170	IUPHAR_LIGAND_ID
5143	INN_ID
NW1291F1W8	UNII
3157	PUBCHEM_CID
39173	RXNORM
37806	MMSL
40546	MMSL
4637	MMSL
d00726	MMSL
003561	NDDF
004493	NDDF
108556006	SNOMEDCT_US
108557002	SNOMEDCT_US
372508002	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2040	TABLET, MULTILAYER, EXTENDED RELEASE	4 mg	ORAL	NDA	28 sections
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2040	TABLET, MULTILAYER, EXTENDED RELEASE	4 mg	ORAL	NDA	28 sections
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2080	TABLET, MULTILAYER, EXTENDED RELEASE	8 mg	ORAL	NDA	28 sections
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2080	TABLET, MULTILAYER, EXTENDED RELEASE	8 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2410	TABLET	1 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2512	TABLET	2 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2614	TABLET	4 mg	ORAL	NDA	28 sections
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2710	TABLET, MULTILAYER, EXTENDED RELEASE	4 mg	ORAL	NDA	28 sections
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2710	TABLET, MULTILAYER, EXTENDED RELEASE	4 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2716	TABLET	8 mg	ORAL	NDA	28 sections
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2720	TABLET, MULTILAYER, EXTENDED RELEASE	8 mg	ORAL	NDA	28 sections
Cardura XL	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2720	TABLET, MULTILAYER, EXTENDED RELEASE	8 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2750	TABLET	1 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2760	TABLET	2 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2770	TABLET	4 mg	ORAL	NDA	28 sections
Cardura	HUMAN PRESCRIPTION DRUG LABEL	1	0049-2780	TABLET	8 mg	ORAL	NDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2067	TABLET	8 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2068	TABLET	4 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2069	TABLET	2 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0093-2070	TABLET	1 mg	ORAL	ANDA	26 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0356	TABLET	1 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-0357	TABLET	2 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1358	TABLET	4 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0832-1359	TABLET	8 mg	ORAL	ANDA	28 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5522	TABLET	1 mg	ORAL	ANDA	18 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5523	TABLET	2 mg	ORAL	ANDA	18 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	0904-5524	TABLET	4 mg	ORAL	ANDA	18 sections
Doxazosin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-292	TABLET	4 mg	ORAL	ANDA	24 sections
Doxazosin Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	10544-629	TABLET	1 mg	ORAL	ANDA	24 sections
Doxazosin	HUMAN PRESCRIPTION DRUG LABEL	1	16590-274	TABLET	4 mg	ORAL	ANDA	12 sections